Extended indication Extension of indication to include treatment as an adjunct to a healthy nutrition and physical activity counselling for weight management in adolescen
Therapeutic value No judgement
Registration phase Registration application pending

Product

Active substance Liraglutide
Domain Metabolism and Endocrinology
Reason of inclusion Indication extension IND
Main indication Other metabolism and Endocrinology
Extended indication Extension of indication to include treatment as an adjunct to a healthy nutrition and physical activity counselling for weight management in adolescent patients from the age of 12 years and above with body weight above 60 kg and obesity (BMI corresponding to ≥30 kg/m2 for adults).
Proprietary name Saxenda
Manufacturer Novo Nordisk
Mechanism of action GLP-1 receptor agonist
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Extramural (GVS)
Additional remarks GLP-1 analoog

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP Unknown
Submission date February 2020
Expected Registration January 2021
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No judgement

This assessment does not indicate any potential inclusion in the package.

Frequency of administration 1 times a day
References NCT02918279

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information